Macrophages can eliminate cancer cells through phagocytosis, which is tightly regulated through inhibition and activation of various phagocytic receptors. In this Review, Veillette and colleagues outline how targeting these phagocytic checkpoints could be harnessed therapeutically, address therapeutic efficacy concerns, and propose strategies to enhance therapeutic outcomes in future clinical applications.